Articles tagged with Cell Therapies
Researchers found that PRP treatment increased gene expression related to metabolism, cell survival, and communication between cells in cumulus cells. This suggests that PRP may help support egg development and fertility in women with poor ovarian response.
Researchers have developed a next-generation CAR-T cell therapy called ALA-CART that can enhance the effectiveness and longevity of cancer cells against harder-to-treat cancers. The treatment has shown promising results in fighting acute lymphocytic leukemias resistant to traditional CAR-T cells.
Researchers discovered that by targeting the Elovl1 enzyme, T cells can harness fatty acid oxidation for energy, increasing their survival and effectiveness against cancer. This metabolic reprogramming approach enhances antitumor activity and improves treatment outcomes in experimental models of melanoma and pancreatic cancer.
Professor Robert T. Schooley will present a talk at the 8th World Congress on Targeting Phage Therapy, exploring phage therapy advancements and necessary steps for widespread adoption. The congress will gather experts to discuss latest advances, challenges, and clinical applications of bacteriophage therapy.
Researchers have discovered a new way to stimulate cardiomyocyte proliferation, offering promising results in both human cardiac slices and live animals. This innovative approach targets calcium signaling pathways, potentially transforming the treatment landscape for patients suffering from heart failure.
PARP inhibitors have been found to be effective in treating cancers with BRCA1/2 mutations by blocking DNA repair pathways. The combination of PARPis with chemotherapeutic drugs can also improve treatment efficacy, increasing DNA damage and blocking repair processes.
A new study reveals that radiotherapy has opposite effects on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), with GBM patients living longer after treatment. The study highlights the need for personalized treatment approaches based on genetic and molecular characteristics to improve survival outcomes.
Researchers have identified a new starting point for therapy by targeting SSAT enzyme in psoriasis, restoring regulatory T cell function and breaking inflammation cycle. This approach could lead to a promising alternative treatment option with fewer side effects.
Researchers discover engineered TIMP molecules can block cancer cell migration and invasion, offering a targeted approach to treating GBM. The findings also suggest the potential for safe treatment with minimal side effects.
Scientists have identified a new target to prevent cold sores by understanding how the herpes virus triggers its own immune response. The discovery has important implications for genital herpes caused by the same virus, with potential treatments in development.
Dermatology researchers have identified a novel skin disease in a male patient with erythroderma, a rare and severe inflammation that causes widespread redness and scaling. Targeted treatment with biologic inhibitors reversed symptoms, providing a promising diagnostic tool for precision-medicine.
The ESMO Targeted Anticancer Therapies Congress 2025 features state-of-the-art presentations on new targets, tumour-agnostic drug development, and the role of artificial intelligence in cancer treatment. The congress also highlights recent study results and their potential impact on precision medicine.
A rare case of T cell lymphoma developed in a patient with multiple myeloma nine months after CAR-T cell therapy. Genetic alterations in the patient's haematopoietic cells played a role in tumour development, highlighting the importance of genetic predispositions for potential side effects.
Mutations in MeCP2 gene lead to depletion of NEAT1, a long non-coding RNA controlling autophagy. Restoring NEAT1 reverses cellular alterations in Rett syndrome models.
Nanomaterials conjugated with drugs improve therapeutic efficacy, reduce toxicity, and enable targeted delivery for neglected tropical diseases. This approach enhances diagnosis with rapid, sensitive, and cost-effective biosensors.
Scientists at Nagoya University have developed a new mRNA technology that can produce up to 200 times more protein than traditional methods. This breakthrough enables the creation of healthy proteins to treat illnesses or toxic proteins to kill unwanted cells.
A new method combines traditional histopathology with spatial transcriptomics data to improve understanding of chronic kidney disease lesions at the cellular and molecular levels. This approach has the potential to identify new biomarkers and therapeutic strategies for patients.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
Researchers at U of T discover a ginger compound called furanodienone that selectively binds to and regulates nuclear receptor PXR, reducing inflammation in the colon. FDN has been shown to increase tight junction proteins, repairing damage to the gut lining caused by inflammation.
Researchers at Pusan National University have developed a novel drug delivery system that uses nanoparticles to target and kill colorectal cancer cells. The system, which involves encapsulating cancer cell-activated nanoconjugates in an alginate matrix, can selectively deliver drugs to tumor cells while minimizing side effects.
Researchers at Virginia Tech have developed a method to convert gut bacteria into mini protein factories that produce and release sustained flows of targeted proteins within the lower intestine. This approach eliminates a major roadblock in delivering drugs to this part of the body, offering potential treatment for chronic diseases.
A team of researchers from the University of Arizona College of Medicine – Tucson found that an FDA-approved osteoporosis treatment, risedronate, can correct a gene mutation and normalize heart function in animal models. The study provides hope for treating other rare diseases using precision treatments tailored to individual mutations.
Scientists at NUS Medicine have developed a novel approach using nasal bacteria to deliver therapeutic molecules directly to the brain, reducing appetite and improving glucose metabolism in preclinical studies. The engineered bacteria leverage the olfactory mucosa's unique properties to deliver medication with enhanced bioavailability.
A new nanomedicine, ZnDHT NM, selectively targets cancer stem-like cells (CSCs) and tumor cells, promoting CSC differentiation while inhibiting EMT. This approach also leads to the release of toxic compounds in tumor cells, inducing apoptosis/ferroptosis pathways.
Researchers have developed a new gene switch that uses nitroglycerine to trigger the production of insulin and regulate blood sugar levels in people with diabetes. This switch is made exclusively of human constituents, eliminating the risk of false triggering or immune reactions.
Researchers have developed a 'gut-on-chip' model that replicates intestinal inflammation and predicts response to immunotherapy in melanoma patients. The device differentiates between major intestinal populations and reproduces realistic environments.
Researchers created optimized DNA hydrogels with fewer nucleic acids, achieving efficient and sustained drug release. The new hydrogel units showed prolonged persistence of at least 168 hours post-administration in mice, contributing to anti-tumor effects.
The Damon Runyon-St. Jude Pediatric Cancer Research Fellowship aims to address a funding gap for pediatric cancer research. The program supports innovative projects that could significantly impact the diagnosis or treatment of one or more pediatric cancers.
Researchers found that flagellin from the gut disrupts immune checkpoint treatment in ovarian cancer patients. Inhibiting this pathway may enhance clinical outcomes and save lives. The discovery could lead to novel therapies capable of targeting ovarian tumors.
Scientists at Duke University have discovered a master epigenetic switch that can be activated using CRISPR to compensate for missing genes in Prader-Willi syndrome. This approach could potentially treat the disease by turning on naturally suppressed genes from one parent, addressing the underlying genetic defect.
Researchers at Virginia Tech have developed a way to convert gut bacteria into miniature protein factories that produce and release targeted proteins inside the lower intestine. This breakthrough could potentially treat chronic diseases.
Researchers discovered that mismatch repair genes are critical in eliciting damages to neurons vulnerable to Huntington's disease, triggering downstream pathologies and motor impairment. Targeting these genes may offer novel therapeutic approaches, including improving locomotor and gait deficits and reducing neuronal cell death.
Researchers at MD Anderson Cancer Center have made significant advancements in treating oligometastatic prostate cancer, advanced urothelial cancer, and triple-negative breast cancer. Personalized risk-based screening is also being explored as a tool to reduce cancer deaths.
Researchers at Osaka Metropolitan University assessed target genes in canine hepatocellular carcinoma (HCC) to develop molecular targeted therapies. The study identified potential gene targets, including PDGFB, which may improve treatment options for unresectable HCC.
A new study reveals that microglia can be reprogrammed from a tumor-promoting state to one that strengthens antitumor responses, reducing brain metastases growth and enhancing immunotherapy responses. Researchers identified a key signaling pathway that, when blocked, reverses the protumoral function of microglia.
Researchers have created an immune map for pancreatic cancer, showing why some tumours are more susceptible to macrophage-based therapies. The study identifies potential avenues for improved treatment approaches, including boosting certain cell responses and depleting suppressive immune cells.
A new liposarcoma treatment using CAR T cells has shown promising results in clinical trials, with a response rate of 20-40% in patients with advanced or metastatic disease. Additionally, researchers have developed more efficient drug-delivery nanoparticles that can improve cancer treatment outcomes.
A Virginia Tech research team has made significant progress in understanding the role of physical properties in tuning the body's immune responses. By modifying biomaterials' size, shape, and stiffness, they aim to enhance immune cell behavior and stimulate antitumor immune responses.
Researchers aim to identify key mechanisms and molecular targets to prevent tumor progression in Rhabdomyosarcoma patients. The study focuses on the TAK1 protein, which plays a significant role in regulating cell growth, and its potential inhibition as a therapeutic approach.
Researchers identified a method to enhance CAR-T cell therapy by modifying the CUL5 gene. This approach improves T cells' growth and longevity, making them more effective in fighting cancer. The study suggests a new way to create targeted cells using a virus to deliver genetic material.
Researchers at UCSF used CRISPR gene editing technology to transform ordinary white fat cells into 'beige' fat cells that voraciously consume calories to make heat. Implanted near tumors, these cells outcompeted cancer cells for nutrients, beating back five types of cancer in lab experiments.
A new study identified USP5 as an enzyme crucial for breaking down unneeded or damaged proteins in the heart. Low levels of USP5 lead to protein buildup, triggering dilated cardiomyopathy in animal models. Increasing USP5 levels helps clear protein 'junk', improving heart function and reducing disease progression.
Researchers developed a computer model called MANAscore to identify tumor-fighting immune cells in lung cancer patients treated with immune checkpoint inhibitors. The three-gene model helped find differences associated with patient response to immunotherapy, including the presence of stem-like memory T cells.
CAR-T cell therapy has been shown to transfer CAR molecules to bystander T cells through trogocytosis, allowing the therapeutic effect to spread beyond the engineered cells. The study reveals that the transmembrane domains of these molecules regulate this process, potentially leading to improved efficacy and reduced side effects.
Researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a chronic inflammatory skin condition. The treatment, baricitinib, selectively blocks specific inflammatory pathways, reducing inflammation and suppressing the overactive immune response that contributes to the disease.
Researchers at Memorial Sloan Kettering Cancer Center have made a breakthrough in creating allogeneic CAR T cells that can persist in fighting cancer without being rejected by patients. By modifying donor cells with the HIV protein Nef, the cells can survive and remain potent in treating various types of cancer.
The foundation has awarded eight recipients of the 2025 Damon Runyon-Rachleff Innovation Award, including five early-career researchers with initial grants of $400,000 over two years. The awardees aim to develop novel cancer therapies using innovative approaches such as engineered skin bacteria and small molecule-boosted drug delivery.
Researchers at the University of Pittsburgh have developed a new way to grow T cells that can live longer and better destroy cancer cells in mice. By adding a compound called dichloroacetate to growth media, they created T cells less reliant on glucose and more efficient at using other energy sources.
Researchers at JAX have successfully alleviated symptoms of multiple sulfatase deficiency using a combination of gene therapy and bone marrow transplantation. The studies, conducted in mice, offer new hope to children with the disease and provide insights into common genetic diseases.
A review of cell death and aging in cancer research reveals the significance of cellular senescence in promoting cancer growth. The study highlights the potential of various types of programmed cell death, such as necroptosis and pyroptosis, as therapeutic targets against senescent cells.
The team's novel technique enables high-throughput screening of nanoparticle shapes, sizes, and modifications, reducing associated screening costs. The research demonstrates the distinct preferences of tumour cells for certain nanoparticle configurations, enabling personalized cancer treatments that are safer and more effective.
The study establishes a consensus nomenclature and characterization framework to advance mitochondria transfer and transplantation biology. It defines types of mitochondrial transfers and reviews methods to define and enforce these processes.
New research reveals that lipid-associated macrophages (LAMs) are crucial for liver repair, while Kupffer cells also adapt to take on a LAM-like phenotype. The Trem2 gene is essential for clearance of dying liver cells and promoting tissue repair.
Researchers have identified a key protein called Apex1 as a potential therapeutic target for stopping the immune system from attacking itself. By inhibiting this protein, harmful T cells that cause autoimmune diseases and allergies can be eliminated.
Researchers reveal senescence's impact on liver health, from repair and regeneration to chronic disease progression. Emerging therapies, such as senolytic treatments, aim to selectively eliminate senescent cells while preserving healthy tissue.
A new study published in Oncotarget discovered an anti-correlation between PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells. This finding suggests the potential for combination therapy to enhance cancer treatment by targeting both markers simultaneously, which could lead to more significant and long-lasting benefits.
Researchers found that a lower CD4+/CD8+ T cell ratio after 12-24 weeks significantly predicted HBsAg clearance in IHCs treated with peginterferon alpha. Higher baseline percentages of CD3+CD8+ cells and lower CD4+/CD8+ ratios were also associated with improved outcomes.
Researchers at UMass Amherst have developed a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. The therapy uses genetically engineered strains of Salmonella that can target tumors and control the release of cancer-fighting drugs inside cancer cells.
Dr. Blagosklonny's work introduced a new theory and promoted the use of rapamycin to slow aging and extend healthy life by targeting the mTOR pathway, leading to improved immune responses, heart protection, and potential cancer prevention.
Researchers at Johns Hopkins Medicine identified a new epigenetic approach to target colorectal cancer, using a mouse protein that disrupts cancer-causing chemical changes in genes. The study found that the protein, STELLA, can be used to develop a drug strategy to treat solid tumors.